Citigroup Inc Cv Rx, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cv Rx, Inc. stock. As of the latest transaction made, Citigroup Inc holds 9,597 shares of CVRX stock, worth $154,991. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,597

Previous 2,894 231.62%

Holding current value

$154,991

Previous $34,000 147.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.15 - $12.37 $47,926 - $82,916	6,703 Added 231.62%	9,597 $84,000
Q2 2024 Aug 12, 2024	BUY	$6.49 - $19.2 $6,600 - $19,526	1,017 Added 54.18%	2,894 $34,000
Q1 2024 May 10, 2024	BUY	$17.99 - $30.49 $4,839 - $8,201	269 Added 16.73%	1,877 $34,000
Q4 2023 Feb 09, 2024	BUY	$11.67 - $33.01 $18,625 - $52,683	1,596 Added 13300.0%	1,608 $50,000
Q3 2023 Nov 09, 2023	SELL	$13.56 - $18.47 $51,690 - $70,407	-3,812 Reduced 99.69%	12 $0
Q2 2023 Aug 10, 2023	SELL	$8.57 - $15.44 $207,076 - $373,076	-24,163 Reduced 86.34%	3,824 $59,000
Q1 2023 May 11, 2023	SELL	$7.08 - $19.4 $2,874 - $7,876	-406 Reduced 1.43%	27,987 $260,000
Q4 2022 Feb 09, 2023	BUY	$8.94 - $18.35 $253,833 - $521,011	28,393 New	28,393 $521,000
Q2 2022 Aug 10, 2022	SELL	$4.7 - $7.22 $3,774 - $5,797	-803 Reduced 87.95%	110 $1,000
Q1 2022 May 12, 2022	SELL	$5.62 - $12.37 $6,221 - $13,693	-1,107 Reduced 54.8%	913 $5,000
Q4 2021 Feb 10, 2022	BUY	$10.65 - $18.61 $11,629 - $20,322	1,092 Added 117.67%	2,020 $25,000
Q3 2021 Nov 10, 2021	BUY	$14.65 - $26.07 $13,595 - $24,192	928 New	928 $15,000

Others Institutions Holding CVRX

# of Institutions

Shares Held

14.4M

Call Options Held

56.3K

Put Options Held

41.8K

View Full List

About CVRx, Inc.

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $332M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

More about CVRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account